Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 51

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Causality Assessment for Suspected DILI During Clinical Phases of Drug Development

Regev, Arie, Seeff, Leonard B., Merz, Michael, Ormarsdottir, Sif, Aithal, Guruprasad P., Gallivan, Jim, Watkins, Paul B. · 2014 · Drug Safety

Abstract

Causality assessment is a critical step in establishing the diagnosis of drug induced liver injury (DILI) during drug development. DILI may resemble almost any type of liver disease, and often presents a serious challenge to clinical investigators and drug makers. The diagnosis of DILI is largely based upon a combination of a compatible clinical course, exclusion of all other reasonable causes, resemblance of clinical and pathological features to known features of liver injury due to the drug (i.e., "drug's signature"), and incidence of liver injury among patients treated with the drug compared to placebo or comparator. Causality assessment for suspected DILI is currently performed using either evaluation by physicians with expertise in liver disorders (i.e., expert opinion) or standardized scoring instruments such as the Roussel Uclaf Causality Assessment Method (RUCAM). Both approaches are widely used in the post marketing setting. Causality assessment based on expert opinion is considered superior to standardized instruments such as RUCAM, in the setting of drug development, and is currently the preferred approach during clinical trials. There is a need for a systematic revision of RUCAM that will render it more suitable for the setting of clinical trials and drug development. Careful monitoring and meticulous data collection during clinical trials are essential in all cases with established liver injury to allow for a proper causality assessment. A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials. This publication is based on the conclusions of this workshop.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40264-014-0185-4

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 33

  1. Chitturi S, Farrell GC. Drug induced liver disease. In: Schiff ER, et al., editors. Schiff’s diseases of the liver. 11th ed. New York: Wiley-Blackwell; 2012. p. 703–82.
  2. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15. · DOI · Paper page
  3. Maria VA, Victorino AJ. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664–9. · DOI · Paper page
  4. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186–95. · DOI · Paper page
  5. Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29(6):667–73. · DOI · Paper page
  6. Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711–4. · DOI · Paper page
  7. Rochon J, Protiva P, Seef LB, et al. Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology. 2008;48:1175–83. · DOI · Paper page
  8. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123–30. · DOI · Paper page
  9. Teschke R, Frenzel C, Schulze J, Schwarzenboeck A, Eickhoff A. Herbalife hepatotoxicity: evaluation of cases with positive reexposure tests. World J Hepatol. 2013;5(7):353–63. · DOI
  10. Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J. Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol. 2014;13(2):248–55. · DOI
  11. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment method: case reports with positive rechallenge. J Clin Epidemiol. 1993;4(6):1331–6. · DOI · Paper page
  12. Papay JI, Clines D, Rafi R, et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009;54(1):84–90. · DOI
  13. Hunt CM. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. Hepatology. 2010;52(6):2216–22. · DOI
  14. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study rationale, design and conduct. Drug Saf. 2009;32:55–68. · DOI · Paper page
  15. Brown G, Copeland T, Willward M, et al. Monadic testing of new products—an old problem and some partial solutions. J Market Res Soc. 1973;15:112–31.
  16. Friedman HH, Amoo T. Rating the rating scales. J Market Manag. 1999;9:114–23.
  17. Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56:422–33. · DOI · Paper page
  18. Hann HW, Hann RS, Maddrey WC. Hepatitis B virus infection in 6,130 unvaccinated Korean–Americans surveyed between 1988 and 1990. Am J Gastroenterol. 2007;102(4):767–72. · doi:10.1111/j.1572-0241.2007.01060.x
  19. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006;4:1076–81. · DOI
  20. Kunihom MH, Purcell RH, McQuillan GM, et al. Epidemiology of hepatitis E virus in the United States: results from the third National Health and National Health and Nutritional Examination survey, 1988–1994. JID. 2009;200:48–56. · DOI · Paper page
  21. Laurent-Puig P, Dussaix E, de Paillette L, et al. Prevalence of hepatitis C RNA in suspected drug induced liver injury (letter). J Hepatol. 1993;19:487–9. · DOI
  22. Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–72. · DOI · Paper page
  23. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–20. · DOI · Paper page
  24. Czaja AJ. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci. 2013;58:897–914. · DOI
  25. Whitehead MW, Hawkes ND, Hainsworth I, et al. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut. 1999;45(1):129–33. · DOI · Paper page
  26. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ. 1999;319(7224):1541. · DOI
  27. Bernal W, Ma Y, Smith HM, et al. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol. 2007;47(5):664–70. · DOI
  28. Marudanayagam R, Shanmugam V, Gunson B, Mirza DF, et al. Aetiology and outcome of acute liver failure. HPB (Oxford). 2009;11(5):429–34. · DOI
  29. Kaymakoglu S, Cakaloglu Y, Demir K, et al. Is severe cryptogenic hepatitis similar to autoimmune hepatitis? J Hepatol. 1998;28(1):78–83. · doi:10.1016/s0168-8278(98)80205-5
  30. Gassert D, Garcia H, Tanako K, et al. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52(9):2433–7. · DOI
  31. Heringlake S, Schütte A, Flemming P, et al. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol. 2009;47(5):417–23. · DOI
  32. Mathiesen UL, Franzén LE, Frydén A, et al. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol. 1999;34(1):85–91. · DOI
  33. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111–8. · DOI · Paper page

Cited by

Metadata

Authors
Regev, A., Seeff, L. B., Merz, M., Ormarsdottir, S., Aithal, G. P., Gallivan, J., & Watkins, P. B.
Venue
Drug Safety
Published
2014-10-29
Volume
37
Issue
S1
Pages
47-56
ISSN
  • 0114-5916
  • 1179-1942
Cited by
51
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.